SCHEMBL6979423

SCHEMBL6979423

O=C(O)[C@H]1O[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
MEN1 O00255 4/20 0.53
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 2/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 1/20 0.44
CAPN1 P07384 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982668 0.86 POLB (0.60) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL9091353 0.83 HSD17B10 (0.54) KMT2AMEN1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL9088919 0.82 MMP8 (0.53) KMT2AMEN1ALDH1A1SMN1; SMN2CAPN1
SCHEMBL6985876 0.78 KMT2A (0.58) KMT2AMEN1ALDH1A1
SCHEMBL6985309 0.77 CAPN1 (0.54) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6981151 0.75 TGM2 (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2CAPN1
SCHEMBL9090621 0.74 ITGA4 (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2TSHR
SCHEMBL6984615 0.74 KMT2A (0.51) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6985559 0.73 CAPN1 (0.58) ALDH1A1KDM4EHSD17B10NPSR1GAA
SCHEMBL9091073 0.73 KMT2A (0.50) KMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed